Novo terminates agreement with Hims & Hers to sell weight-loss drug
HQ Team June 23, 2025: Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc.,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 23, 2025: Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc.,.
HQ Team March 21, 2025: A study from China adds to mounting evidence that semaglutide—a medication widely used for type 2 diabetes (Ozempic).
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
HQ Team December 13, 2024: Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
HQ Team November 8, 2024: The rise of weight loss medications such as Ozempic (semaglutide) and Wegovy has sparked significant interest and usage.
HQ Team August 22, 2024: A new study based on data from the World Health Organization’s records on adverse drug reactions found that.
HQ Team July 31, 2024: A new research published in the Annals of Internal Medicine reveals that semaglutide is effective in helping people quit.
Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.
Research finds a sharp increase in use of weightloss drugs such as Ozempic and Wegovy among teens and young adults
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.